Stablor treats the dysfunctional metabolic processes associated with abdominal obesity

Published: 18-Nov-2014

Obeminale programme demonstrates the safety and efficacy of the product, with an average of 18% fat loss and 9% weight loss in overweight and obese people


LNC (Laboratoires Nutrition et Cardiometabolisme), a French research and development company specialising in chronic metabolic diseases based in Bordeaux, says the first results of its Obeminale programme demonstrate both the safety and efficacy of the medical food Stablor.

This novel patented product targets the underlying causes of abdominal obesity and demonstrates a reduction in the cardiometabolic risk factors associated with obesity co-morbidities (high triglycerides, hyperglycemia and low HDL cholesterol).

Consolidated results from two clinical studies and product usage in real clinical practice demonstrate that in less than six months Stablor delivers 18% fat loss, mostly in the waist area; 9% weight loss; 9.5% decrease in waist circumference; at least 5% weight loss for 67% of patients and a high level of safety.

Stablor is composed of amino acids and micronutrients. It has been engineered to decrease adipocyte dysfunction and adipose tissue inflammation. Additional clinical results have confirmed a significant decrease in inflammation (CRPus -11%) and a positive impact on insulin-resistance (HOMA IR -24%).

This novel patented product targets the underlying causes of abdominal obesity

According to a recent report from the Journal of the American Medical Association (JAMA), the number of people with abdominal obesity (visceral fat) increased from 46.4% of the US population in 1999-2000 to 54.2% in 2011-2012.

LNC says Stablor is now ready for market and can be prescribed to any individual with abdominal obesity and co-morbidities.

The final results of the Obeminale programme, to be published in early 2015, will include microbiota and adipose tissue details.

LNC has four additional programmes under development: medical foods targeting metabolic disorders related to subfertility, bariatric surgery, pre-diabetes and Non-Alcoholic SteatoHepatitis (NASH), with successive market launches planned over the next four years.

You may also like